Drugs / CD1a-CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05679895 | Jan 2023 → Dec 2027 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | OneChain Immunotherapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD1a-CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05679895 ↗ |
| Modality | Cell therapy | “Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus” NCT05679895 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05679895 ↗ |
| Target | CD1A | “CD1a chimeric antigen receptor” NCT05679895 ↗ |